Best-in-class therapeutics
Leveraging proven mechanisms of action

PurMinds' science team is developing next generation therapeutics for neurological disorders by harnessing an innovative approach to drug development based on partnerships with industry peers and academia with a focus on best-in-class novel therapeutics. 

 

We believe neuroplastogens and psychoplastogens offer new beacon of hope for Central Nervous System diseases, riding on exciting clinical data and recognition by regulatory bodies and the scientific community for psychiatric and neurological conditions where traditional therapies have largely failed. 

 

PurMinds’ small molecule programs (PUR501 and PUR400) are invented by our Chief Scientific Officer, Dr. Alan Kozikowski, who is world renowned for his work in the area of medicinal chemistry designing NCEs for both cancer and CNS disorders, and in particular, in the areas of 5-HT, HDAC, and GSK-3 therapeutics. We also have an in-house formulation team who have developed our proprietary psilocybin formulation for various indications.